Skip to main content

STK 05: Antithrombotic Therapy By End of Hospital Day Two

CBE ID
0438
1.4 Project
Endorsement Status
Previous Endorsement Cycle
Is Under Review
No
1.3 Measure Description

This measure captures the proportion of ischemic stroke patients who had antithrombotic therapy administered by end of hospital day two (with the day of arrival being day 1).

This measure is a part of a set of eight nationally implemented measures that address stroke care (STK-1: Venous Thromboembolism (VTE) Prophylaxis, STK-2: Discharged on Antithrombotic Therapy, STK-3: Anticoagulation Therapy for Atrial Fibrillation/Flutter, STK-4: Thrombolytic Therapy, STK-6: Discharged on Statin Medication, STK-8: Stroke Education, and STK-10: Assessed for Rehabilitation) that are used in The Joint Commission’s hospital accreditation and Disease-Specific Care certification programs.

        • 1.14 Numerator

          Ischemic stroke patients who had antithrombotic therapy administered by
          end of hospital day two.

        • 1.15 Denominator

          Ischemic stroke patients

        • Exclusions

          • Less than 18 years of age
          • Duration of Stay < 2 days
          • Length of Stay > 120 days
          • Comfort measures only documented on the day of or day after hospital arrival
          • Enrolled in clinical trials related to stroke
          • Admitted for elective carotid intervention
          • IV OR IA thrombolytic therapy administered at this hospital or within 24 hours prior to arrival
          • Documented reason for not administering antithrombotic therapy by end of hospital day 2

        • Most Recent Endorsement Activity
          Endorsed with Reserve Status Neurology Project 2015-2016
          Initial Endorsement
          Last Updated
        • Steward
          The Joint Commission
          Steward Organization POC Email
          Steward Organization Copyright

          No royalty or use fee is required for copying or reprinting this manual, but the following are required as a condition of usage: 1) disclosure that the Specifications Manual is periodically updated, and that the version being copied or reprinted may not be up-to-date when used unless the copier or printer has verified the version to be up-to-date and affirms that, and 2) users participating in Joint Commission accreditation, including ORYX® vendors, are required to update their software and associated documentation based on the published manual production timelines.